Rituximab or biosimilar

DRUG2 trials

Sponsors

Sanofi, Columbia University

Conditions

Anemia, Sickle CellTransplant Rejection

Phase 1

Siplizumab for Sickle Cell Disease Transplant

TerminatedNCT06078696

Columbia UniversityAnemia, Sickle Cell

Start: 2023-09-28End: 2025-12-11Updated: 2026-02-27

Phase 2

BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)

Active, not recruitingNCT05156710

SanofiTransplant Rejection

Start: 2022-06-09End: 2026-10-26Updated: 2026-02-24